Nifedipine/atenolol interactions in gastrointestinal absorption and biotransformation.
The combination of nifedipine and atenolol is widely used for the treatment of hypertension. In the present study, experiments performed in rats indicated that neither drug affects the gastric or intestinal absorption of the other. In assays of the biotransformation of nifedipine in liver homogenates, breakdown was much more rapid in homogenates from male rats than from female rats. In the presence of atenolol, the breakdown rate was significantly increased in homogenates from male rats, and significantly reduced in homogenates from female rats.
Iglesias
R
R
Departamento de Farmacología, Farmacia y Tecnología, Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela, Spain.
Taboada
C
C
Souto
C
C
Martínez-Pacheco
R
R
Gómez-Amoza
J L
JL
Concheiro
A
A
D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology*; D000818:Animals; D001262:Atenolol / Q000493:pharmacokinetics / Q000494:pharmacology*; D001711:Biotransformation; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D004347:Drug Interactions; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism; D007408:Intestinal Absorption / Q000187:drug effects*; D007421:Intestine, Small / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009543:Nifedipine / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013270:Stomach / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D001262:Atenolol; D009543:Nifedipine